Krystal Biotech, Inc.
KRYS
$143.96
-$2.34-1.60%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | 146.73M | 123.96M | 89.16M | 52.37M | 105.94M |
| Total Depreciation and Amortization | 2.16M | 3.14M | 3.21M | 3.88M | 4.32M |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 52.02M | 50.69M | 45.50M | 41.91M | -64.50M |
| Change in Net Operating Assets | -5.51M | -39.29M | -14.46M | -34.82M | -62.50M |
| Cash from Operations | 195.40M | 138.50M | 123.42M | 63.35M | -16.74M |
| Capital Expenditure | -9.96M | -9.18M | -4.24M | -5.28M | -6.02M |
| Sale of Property, Plant, and Equipment | 435.00K | -- | -- | 0.00 | 100.00M |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -173.88M | -183.05M | -159.20M | -84.54M | -44.28M |
| Cash from Investing | -183.40M | -192.23M | -163.44M | -89.82M | 49.70M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 9.05M | 17.89M | 32.40M | 32.59M | 42.61M |
| Repurchase of Common Stock | -13.93M | -13.93M | -5.39M | -5.39M | -5.39M |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -4.88M | 3.97M | 27.01M | 27.21M | 37.23M |
| Foreign Exchange rate Adjustments | 922.00K | -474.00K | -458.00K | -4.00K | -278.00K |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 8.04M | -50.24M | -13.46M | 725.00K | 69.91M |